Global Long-acting Injectable Medications Market Size, Status and Forecast 2022

Long-acting injectables (LAIs) are unique tools used in psychiatric pharmacy to help improve patient outcomes. They offer a number of benefits compared to oral therapy, including confirmed patient adherence, consistent drug delivery, predictable bioavailability and prevention of antipsychotic overdoses. Its origins in indications such as schizophrenia and contraception, also HIV treatment and prevention.

Market Analysis and Insights: Global Long-acting Injectable Medications Market
In 2021, the global Long-acting Injectable Medications market size will be US$ million and it is expected to reach US$ million by the end of 2027, with a CAGR of % during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Long-acting Injectable Medications market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Long-acting Injectable Medications market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Long-acting Injectable Medications market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Long-acting Injectable Medications market.

Global Long-acting Injectable Medications Scope and Market Size
Long-acting Injectable Medications market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Long-acting Injectable Medications market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
First-generation
Second-generation

Segment by Application
Schizophrenia
Contraception
HIV
Others

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Eli Lilly
Alkermes
Johnson & Johnson
Zogenix
DURECT
Mapi Pharma
GSK
MedinCell
Oakwood Labs
Nanomi
Pharmathen
Kashiv BioSciences